Actinium Pharmaceuticals (ATNM) Operating Leases (2019 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Operating Leases of $785000.0 for Q1 2026, down 6.1% year-over-year from $836000.0 in Q1 2025, and down 19.24% quarter-over-quarter from $972000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Operating Leases (2019 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Operating Leases for 8 consecutive years, with $785000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 6.1% year-over-year to $785000.0; the TTM figure through Mar 2026 stood at $785000.0 (down 6.1% YoY), while the FY2025 annual figure was $972000.0, down 1.22% from the prior year.
- Operating Leases eased to $785000.0 in Q1 2026 per ATNM's latest filing, from $972000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $2.2 million in Q3 2022 and bottomed at $531000.0 in Q3 2025.
- Historically, Operating Leases has averaged $1.4 million across 5 years, with a median of $1.3 million in 2024.
- On a YoY basis, Operating Leases climbed as much as 1.22% in 2025 and fell as far as 53.38% in 2025.
- Actinium Pharmaceuticals' Operating Leases stood at $2.1 million in 2022, then retreated by 25.44% to $1.6 million in 2023, then slumped by 36.64% to $984000.0 in 2024, then decreased by 1.22% to $972000.0 in 2025, then retreated by 19.24% to $785000.0 in 2026.
- Business Quant data shows ATNM's Operating Leases at $785000.0 in Q1 2026, $972000.0 in Q4 2025, and $531000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 595,000.00 |
| Mar 31, 2026 | 785,000.00 |
| Dec 31, 2025 | 972,000.00 |
| Sep 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 685,000.00 |
| Mar 31, 2025 | 836,000.00 |
| Dec 31, 2024 | 984,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.95 Mn |
| Dec 31, 2022 | 2.08 Mn |
| Sep 30, 2022 | 2.21 Mn |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 154,000.00 |
| Dec 31, 2020 | 245,000.00 |
| Sep 30, 2020 | 333,000.00 |